Yesterday was a wonderful day, my favorite molecule to which I have been dedicating a great part of my professional life, RNA, was given value again ?? . Researchers Victor Ambros and Gary Ruvkun were awarded for their contribution to the discovery of miRNAs and their regulatory role in RNA.
Today starts the day with a second piece of news that makes this week special: the Nobel Prize in Physics 2024 is awarded to John Hopfield and Geoffrey Hinton for the work on artificial intelligence (IA) that has been the basis for the development of ML and neural networks, my second favorite thing. ??
This work is the basis for many predictive models that live with all of us in our lives, but are a paradigm shift in many fields such as the pharmaceutical industry.
?ML, AI has come to change the status quo in this field. Helping professionals to make their processes more efficient and productive, to infer new information, explore new paths, offer new alternatives to reduce time for patients, and try to improve the characteristics of these drugs by incorporating features in predictive models that make them better and better, quickly and without spending years of research and money, something quite common in the pharmaceutical industry.
Using technology to get novel drugs to the patient faster and better each time is a challenge and a responsibility. Relying on technology to walk this path is a help and an exciting challenge that can only be used to make things better. Ultimately working to improve people's lives. I am pleased about these two Nobel Prizes and grateful to have the possibility,?in my daily life,?to work with both technologies. siRNAs, miRNAs and AI ?? .
At SYLENTIS today we are celebrating that these technologies are taking center stage in our daily lives, and we rely on them to try to make things better every day.
Thanks to the laureates for their work for their contribution to the world and for giving us tools to other people to try to make this world a little better with small contributions. ??